AIMD
Ainos, Inc.
There isn't enough reported data to score AIMD yet.
UNH
UnitedHealth Group Incorporated
UNH's fundamentals are mixed: free cash flow grew 31%, but earnings per share fell 8.5%. At 23x earnings, it's trading right at its usual valuation. Analysts expect strong earnings growth, though they disagree widely on how much.
AIMD Fundamentals
| Metric | Status |
|---|---|
| Weak | |
| Weak | |
| Weak | |
| Unavailable |
AIMD's revenue, profitability and cash flow are currently weak. There isn't enough data to rate its balance sheet.
UNH Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Stable | |
| Healthy | |
| Healthy |
UNH's cash flow and balance sheet are currently healthy, and its revenue and profitability are stable.
AIMD PE Valuation
AIMD has no meaningful PE right now: it lost money over the past year.
UNH PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 18x | $405 | — |
| Cheap | 19x | $325 | -20% |
| Fair | 23x | $410 | +1.2% |
| Current | 23x | $405 | — |
| Expensive | 30x | $526 | +30% |
Historical ranges are pointers, not guarantees.
UNH's PE is in its fair range at 23x. If earnings grow as analysts expect, today's price would be 18x next year's earnings, in its cheap range.
AIMD Forward outlook
There aren't enough analyst estimates for AIMD to show an outlook.
UNH Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Stable | |
| Improving | |
| Moderate | |
| Low |
Analysts expect UNH's earnings to grow and its profitability to improve, with its revenue holding steady. However, they disagree widely on these estimates.
AIMD Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | -$3.29 | +$1.25 |
| Q1 2026 | -$3.66 | +$2.34 |
| Q4 2025 | -$4.30 | +$3.50 |
| Q2 2021 | -$11.25 | +$7.50 |
| Q1 2021 | -$15.00 | $0.00 |
| Q4 2020 | -$15.00 | $0.00 |
| Q3 2020 | -$18.75 | -$3.75 |
AIMD is still losing money, but far less than before: $3.29 per share over the past year, against $18.75 at its worst in mid-2020.
UNH Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $22.65 | +29% |
| Q3 2026 | $17.55 | -8.5% |
| Q2 2026 | $15.58 | -33% |
| Q1 2026 | $13.28 | -44% |
| Q4 2025 | $13.23 | -15% |
| Q3 2025 | $19.17 | +25% |
| Q2 2025 | $23.09 | +53% |
| Q1 2025 | $23.89 | +46% |
| Q4 2024 | $15.51 | -35% |
UNH has the edge over AIMD on earnings quality, reporting a profit while its opponent remains loss making.
AIMD Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $152 | -97% |
| Q1 2026 | $161 | -100% |
| Q1 2025 | $106.2K | +412% |
| Q1 2024 | $20.7K | -58% |
| Q4 2023 | $19.9K | -98% |
| Q3 2023 | $24.5K | -99% |
| Q2 2023 | $28.6K | -96% |
| Q1 2023 | $49.2K | -44% |
AIMD's revenue has slid since its 2022 peak: $152 last quarter, down 97% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | -2894136% | -2813808 points |
| Q1 2026 | -1418414% | -1415436 points |
| Q4 2025 | -38648% | N/A |
| Q3 2025 | -128481% | N/A |
| Q2 2025 | -80328% | N/A |
| Q1 2025 | -2978% | +12074 points |
| Q1 2024 | -15052% | -9940 points |
| Q4 2023 | -28643% | -28438 points |
AIMD's operating margin was −2894136% last quarter, down 2813808 points from the same quarter a year ago, near the bottom of its range since 2019.
UNH Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $112.7B | -0.4% |
| Q2 2026 | $112B | +0.4% |
| Q1 2026 | $111.7B | +2% |
| Q4 2025 | $113.2B | +12% |
| Q3 2025 | $113.2B | +12% |
| Q2 2025 | $111.6B | +13% |
| Q1 2025 | $109.6B | +9.8% |
| Q4 2024 | $100.8B | +6.8% |
UNH has the edge over AIMD on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 5.8% | +2 points |
| Q2 2026 | 7.1% | +2.5 points |
| Q1 2026 | 8.1% | -0.3 points |
| Q4 2025 | 0.3% | -7.4 points |
| Q3 2025 | 3.8% | -4.8 points |
| Q2 2025 | 4.6% | -3.4 points |
| Q1 2025 | 8.3% | +0.4 points |
| Q4 2024 | 7.7% | -0.4 points |
UNH has the edge over AIMD on profitability, with a higher operating margin.
AIMD Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | -$1.5M | -$111.4K |
| Q1 2026 | -$992K | +$266.3K |
| Q4 2025 | -$853.5K | +$11.7K |
| Q3 2025 | -$1.2M | +$290.5K |
| Q2 2025 | -$1.3M | +$637.3K |
| Q1 2025 | -$1.3M | +$241K |
| Q4 2024 | -$865.1K | +$492.9K |
| Q2 2024 | -$2M | -$829K |
AIMD has burned cash in almost every quarter: −$4M over the past year, against −$5M the year before.
UNH Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $4.3B | -16% |
| Q2 2026 | $10.3B | +63% |
| Q1 2026 | $8.1B | +79% |
| Q4 2025 | $160M | -89% |
| Q3 2025 | $5.1B | -61% |
| Q2 2025 | $6.3B | +6.9% |
| Q1 2025 | $4.6B | +1037% |
| Q4 2024 | $1.5B | +$7.6B |
UNH has the edge over AIMD on cash generation, producing positive trailing cash flow while its opponent burns cash.
AIMD Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +22% | +1.3M shares |
| 1 year | +132% | +4.2M shares |
| 3 years | +819% | +6.6M shares |
| 5 years | +6709% | +7.2M shares |
AIMD has 7M diluted shares, up 132% from a year ago.
UNH Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.4% | -4M shares |
| 1 year | -0.7% | -6M shares |
| 3 years | -3.6% | -34M shares |
| 5 years | -5.5% | -53M shares |
| Available history | -6.6% | -64M shares |
UNH has the edge over AIMD on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $3.4B |
| Q2 2026 | $1.6B |
| Q1 2026 | — |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | $2.5B |
| Q1 2025 | $3B |
| Q4 2024 | $5B |
UNH spent $5B buying back its own shares over the past year, down 52% from the year before.
AIMD Net Leverage
AIMD's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
UNH Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.7x | Healthy |
| Q2 2026 | 1.7x | Healthy |
| Q1 2026 | 2.2x | Moderate |
| Q4 2025 | 2.3x | Moderate |
| Q3 2025 | 1.7x | Healthy |
| Q2 2025 | 1.5x | Healthy |
| Q1 2025 | 1.3x | Healthy |
| Q4 2024 | 1.4x | Healthy |
UNH's net debt is about 1.7 years of its operating earnings (EBITDA), about the same as a year ago.
AIMD Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 42.6 | Neutral |
| Stochastic | 19.5 | Oversold |
AIMD's weekly RSI is 43 (neutral) and its Stochastic is 20 (oversold).
UNH Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 56.4 | Neutral |
| Stochastic | 60.0 | Neutral |
UNH's weekly RSI is 56 (neutral) and its Stochastic is 60 (neutral).
AIMD PE vs Healthcare Sector
AIMD has no meaningful PE right now: it lost money over the past year.
UNH PE vs Healthcare Sector
| Metric | UNH | Sector median | Relative |
|---|---|---|---|
| PE | 23x | 26x | 11% below |
| PE % | 47 | 29 | 18 pts above |
UNH is trading at 23x earnings, a 11% discount to the Healthcare sector's median of 26x.
AIMD Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1.01 | 5% above |
| 20 week MA | $1.32 | 20% below |
| 50 week MA | $1.60 | 34% below |
| 100 week MA | $2.30 | 54% below |
| 200 week MA | $6.77 | 84% below |
AIMD has bounced recently, but its long-term trend is still down: it's above its 8-week average, but 84% below its 200-week average.
UNH Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $394.2 | 2.8% above |
| 20 week MA | $400.5 | 1.2% above |
| 50 week MA | $361.2 | 12% above |
| 100 week MA | $376.0 | 7.8% above |
| 200 week MA | $446.6 | 9.3% below |
UNH has the edge over AIMD on trend strength, trading above more of its moving averages.
AIMD Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $57.4 | $255.0 | +344% |
| 2022 | $255.0 | $15.7 | -94% |
| 2023 | $15.7 | $10.3 | -35% |
| 2024 | $10.3 | $2.27 | -78% |
| 2025 | $2.27 | $1.95 | -14% |
| 2026 YTD | $1.95 | $1.06 | -46% |
AIMD has finished four years in a row lower, and it's down 46% so far in 2026.
UNH Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $296.0 | $340.8 | +15% |
| 2021 | $340.8 | $495.4 | +45% |
| 2022 | $495.4 | $531.3 | +7.3% |
| 2023 | $531.3 | $526.5 | -0.9% |
| 2024 | $526.5 | $510.0 | -3.1% |
| 2025 | $510.0 | $331.8 | -35% |
| 2026 YTD | $331.8 | $405.1 | +22% |
UNH has the edge over AIMD on returns for 2026, with the stronger performance.